0000000000150376

AUTHOR

Pietro Gambadauro

0000-0003-1568-4575

showing 3 related works from this author

Office 2.0: a web 2.0 tool for international collaborative research

2008

World Wide WebInternetEngineeringWeb 2.0business.industryCommunicationInternational CooperationResearchGeneral MedicinebusinessThe Lancet
researchProduct

Endometrial receptivity and implantation are not affected by the presence of uterine intramural leiomyomas: a clinical and functional genomics analys…

2008

Uterine leiomyomas are the most frequent benign tumors during reproductive age. Whether intramural leiomyomas cause infertility and should be removed is controversial because no study has addressed the underlying mechanism of infertility.The objective of the study was to test the effect of intramural leiomyomas on endometrial function by comparing gene during the window of implantation and implantation in an oocyte donation program, in which the quality of the embryos replaced is similar and the endocrine environment of the endometrium is standardized by exogenous steroids.Human endometria of women with single intramural leiomyomas (group A,5 cm and group B,or =5 cm) and controls (group C) …

InfertilityAdultmedicine.medical_specialtyPregnancy RateEndocrinology Diabetes and Metabolismmedicine.medical_treatmentClinical BiochemistryUterusContext (language use)BiologyEndometriumBiochemistryModels BiologicalEndometriumEndocrinologyPregnancyInternal medicinemedicineCluster AnalysisHumansEmbryo ImplantationOligonucleotide Array Sequence AnalysisRetrospective StudiesGynecologyIn vitro fertilisationUterine leiomyomaLeiomyomaGene Expression ProfilingBiochemistry (medical)GenomicsMiddle Agedmedicine.diseaseGene Expression Regulation NeoplasticPregnancy ratemedicine.anatomical_structureEndocrinologyIn uteroUterine NeoplasmsFemalePregnancy Complications NeoplasticThe Journal of clinical endocrinology and metabolism
researchProduct

Gefitinib in lung cancer therapy. Clinical results, predictive markers of response and future perspectives.

2009

Over the past few years, epidermal growth factor receptor has emerged as one of the most important targets in tumorgenesis and several drugs targeting signal transduction pathways have been developed. The first among these agents to be approved for the treatment of NSCLC was gefitinib, a potent, selective and reversible inhibitor of HER1/EGFR tyrosine kinase activity. The review summarizes its clinical development and the new therapeutic options, with particular focus on predictive markers of susceptibility to this drug.

DrugOncologyCancer Researchmedicine.medical_specialtyLung Neoplasmsmolecular markersmedia_common.quotation_subjectgefitinibAntineoplastic AgentsGefitinibcancer therapyGefitinibCarcinoma Non-Small-Cell LungInternal medicinetyrosine kinase inhibitorsmedicineAnimalsHumansgefitinib; non-small cell lung cancer (NSCLC); epidermal growth factor receptor (HER1/EGFR); tyrosine kinase inhibitors; target therapy; molecular markers; EGFR mutationsEpidermal growth factor receptorLung cancermedia_commonPharmacologyClinical Trials as Topicbiologybusiness.industrytarget therapymedicine.diseaseEGFR mutationsepidermal growth factor receptor (HER1/EGFR)ErbB Receptorsnon-small cell lung cancer (NSCLC)OncologyQuinazolinesbiology.proteinMolecular MedicineSignal transductionbusinessBiomarkersEgfr tyrosine kinaseSignal Transductionmedicine.drug
researchProduct